These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 17196444)

  • 1. Starting from scratch: program development and lessons learned from HIV vaccine trial counseling in Thailand.
    Thapinta D; Jenkins RA
    Contemp Clin Trials; 2007 Jul; 28(4):409-22. PubMed ID: 17196444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic vaccine trails in Thailand.
    Churdboonchart V
    J HIV Ther; 2004 Sep; 9(3):57-9. PubMed ID: 15534562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incentives and disincentives to participate in prophylactic HIV vaccine research.
    Jenkins RA; Temoshok LR; Virochsiri K
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 May; 9(1):36-42. PubMed ID: 7712233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statistical evaluation of HIV vaccines in early clinical trials.
    Moodie Z; Rossini AJ; Hudgens MG; Gilbert PB; Self SG; Russell ND
    Contemp Clin Trials; 2006 Apr; 27(2):147-60. PubMed ID: 16426900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Social harms in injecting drug users participating in the first phase III HIV vaccine trial in Thailand.
    Pitisuttithum P; Choopanya K; Bussaratid V; Vanichseni S; van Griensven F; Phonrat B; Martin M; Vimutsunthorn E; Sangkum U; Kitayaporn D; Tappero JW; Heyward W; Francis D
    J Med Assoc Thai; 2007 Nov; 90(11):2442-8. PubMed ID: 18181333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of attitude, risk behavior and expectations among Thai participants in Phase I/II HIV/AIDS vaccine trials.
    Maek-A-Nantawat W; Pitisuttithum P; Phonrat B; Bussaratid V; Naksrisook S; Peonim W; Thantamnu N; Muanaum R
    J Med Assoc Thai; 2003 Apr; 86(4):299-307. PubMed ID: 12757073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preventive HIV vaccine acceptability and behavioral risk compensation among high-risk men who have sex with men and transgenders in Thailand.
    Newman PA; Roungprakhon S; Tepjan S; Yim S
    Vaccine; 2010 Jan; 28(4):958-64. PubMed ID: 19925897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Domestic AIDS vaccine trials: addressing the potential for social harm to the subjects of human experiments.
    Leider PA
    Calif Law Rev; 2000; 88():1185-232. PubMed ID: 11067733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-vaccine research and development in Thailand: evolution and challenges.
    Pitisuttithum P; Choopanya K; Rerk-Ngnam S
    Vaccine; 2010 May; 28 Suppl 2():B45-9. PubMed ID: 20510743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategies for addressing the social and behavioral challenges of prophylactic HIV vaccine trials.
    Chesney MA; Lurie P; Coates TJ
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 May; 9(1):30-5. PubMed ID: 7712232
    [No Abstract]   [Full Text] [Related]  

  • 11. HIV vaccine research in Thailand: lessons learned.
    Pitisuttithum P
    Expert Rev Vaccines; 2008 Apr; 7(3):311-7. PubMed ID: 18393601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Executive summary and recommendations from the WHO/UNAIDS/IAVI expert group consultation on 'Phase IIB-TOC trials as a novel strategy for evaluation of preventive HIV vaccines', 31 January-2 February 2006, IAVI, New York, USA.
    WHO/UNAIDS/IAVI International Expert Group
    AIDS; 2007 Feb; 21(4):539-46. PubMed ID: 17301582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Large HIV vaccine trial begins.
    Santiago L
    GMHC Treat Issues; 1998 Oct; 12(10):1-5. PubMed ID: 11365900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk behaviours and comprehension among intravenous drug users volunteered for HIV vaccine trial.
    Pitisuttithum P; Migasena S; Laothai A; Suntharasamai P; Kumpong C; Vanichseni S
    J Med Assoc Thai; 1997 Jan; 80(1):47-50. PubMed ID: 9078816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV vaccine trials: reconsidering the therapeutic misconception and the question of what constitutes trial related injuries.
    Schüklenk U; Ashcroft R
    Dev World Bioeth; 2007 Dec; 7(3):ii-iv. PubMed ID: 18021115
    [No Abstract]   [Full Text] [Related]  

  • 16. HIV/AIDS preventive vaccine 'prime-boost' phase III trial: foundations and initial lessons learned from Thailand.
    Rerks-Ngarm S; Brown AE; Khamboonruang C; Thongcharoen P; Kunasol P
    AIDS; 2006 Jul; 20(11):1471-9. PubMed ID: 16847401
    [No Abstract]   [Full Text] [Related]  

  • 17. Army HIV vaccine to undergo clinical trial as rival is halted.
    Check E
    Nature; 2002 Mar; 416(6876):6. PubMed ID: 11882860
    [No Abstract]   [Full Text] [Related]  

  • 18. Correlates of HIV vaccine trial participation: an Indian perspective.
    Sahay S; Mehendale S; Sane S; Brahme R; Brown A; Charron K; Beyrer C; Bollinger R; Paranjape R
    Vaccine; 2005 Feb; 23(11):1351-8. PubMed ID: 15661383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preventive HIV vaccine development in Thailand.
    Nitayaphan S; Brown AE
    AIDS; 1998; 12 Suppl B():S155-61. PubMed ID: 9679641
    [No Abstract]   [Full Text] [Related]  

  • 20. Racial and ethnic differences in knowledge and willingness to participate in HIV vaccine trials in an urban population in the Southeastern US.
    Priddy FH; Cheng AC; Salazar LF; Frew PM
    Int J STD AIDS; 2006 Feb; 17(2):99-102. PubMed ID: 16464270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.